| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 107,914 | 124,192 | ||
| Marketable securities | 419,375 | 381,228 | ||
| Prepaid expenses and other current assets | 12,808 | 10,702 | ||
| Total current assets | 540,097 | 516,122 | ||
| Long-term marketable securities | 61,640 | 115,769 | ||
| Property and equipment, net | 6,032 | 6,438 | ||
| Right-of-use asset, net | 9,646 | 10,586 | ||
| Other non-current assets | 8,744 | 8,857 | ||
| Total assets | 626,159 | 657,772 | ||
| Accounts payable | 376 | 5,678 | ||
| Lease liability | 4,079 | 4,025 | ||
| Accrued expenses and other current liabilities | 29,592 | 21,848 | ||
| Total current liabilities | 34,047 | 31,551 | ||
| Lease liability, net of current | 5,774 | 6,820 | ||
| Total liabilities | 39,821 | 38,371 | ||
| Common stock 0.00001 par value, 400,000,000 authorized, 60,147,727 issued and 59,315,738 outstanding as of september 30, 2025 400,000,000 authorized, 59,478,725 issued and 58,062,898 outstanding as of december 31, 2024 | 1 | 1 | ||
| Additional paid-in capital | 1,077,681 | 1,046,066 | ||
| Accumulated other comprehensive income | 1,028 | 685 | ||
| Accumulated deficit | -492,372 | -427,351 | ||
| Total stockholders' equity | 586,338 | 619,401 | ||
| Total liabilities and stockholders' equity | 626,159 | 657,772 | ||
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)